Global Investor Forum Contact

Frits Schut

Partner, V.O. Patents&Trademarks

Session

11:30 - 12:45
IP Valuation

Track leader

Frits Schut has been involved in patenting since 1995, when exploiting patented inventions of which he was a co-inventor in a biotech startup.
Frits studied biology at the universities of Utrecht, Amsterdam and obtained his PhD in microbiology from the university of Groningen. While performing part of his PhD work at the University of Alaska Fairbanks he came into contact with molecular genetics and DNA diagnostics. He was able to further develop these techniques for medical and veterinary application with the Medical faculty in Groningen and these developments were commercially implemented in a startup diagnostic company, of which he was a co-director.
Frits joined V.O. in 2001. He has broad expertise, and is particularly involved in therapeutic and diagnostic (medical) biotechnology, microbiology and plant protection. Both because of his background and portfolio, Frits has special experience with Life Science companies aiming to protect their essential technologies. He has a wide experience in patent cases before the European Patent Office and the Court of The Hague. Frits also has experience with plant protection before the Dutch and Community Plant Variety Office

Abstract

Academia and industry – doomed relationship?
Academic research institutes are cradles of knowledge and inventions, sometimes resulting in successful products that are commercialized by industry. Collaborations between academia and industry are not always easy. There may be a different appreciation of the length and risk of the development process needed to transform an invention into a successful product. This may result in different expectations as to the value of the invention. These opposing perspectives may complicate a fruitful collaboration. But what formats can lead to mutual benefit? Do both partners need each other? Is it important to patent the invention, and what rules for ownership may apply? In this track, representatives from both sides will give their opinion on requirements for a successful collaboration.

Kees Been
Lysosomal Therapeutics Inc.

Erik van de Berg
AM-Pharma

René Bernards
Qameleon Therapeutics & NKI

Annelien Bredenoord
UMC Utrecht

Carine van den Brink
AXON Lawyers

Danielle Curfs
Chemelot InSciTe
Jenny Dankelman
TU Delft
Diederik Dippel
Erasmus MC

Cornelia van Duijn
Erasmus MC

Lude Franke
UMCG
Thibault Helleputte
DNAlytics
Mark van Houdenhoven
St. Maartenskliniek
Henk Joos
Flanders Bio
Peter de Keizer
Erasmus MC
Tim Knotnerus
AM-Pharma, PRIMER Professionals
Angus Livingstone
Oncode Institute
Travis McCready
Massachusetts Life Sciences Center

Mirjam Mol
Pivot Park

Barend Mons
DTL & LUMC
Timothy Noël
Eindhoven University of Technology
Jacquelien Noordhoek
Dutch CF Foundation
Violet Petit-Steeghs
Athena Institute
Thomas Plochg
NPHF
Dirk Jan van der Pol
Ordina
Anne Portwich
LSP
Elisabeth van Rossum
Erasmus MC
André van de Sande
Xendo
Marlies Schijven
AMC
Hans Schikan
Topsector LSH
Hanneke Schuitemaker
Janssen Vaccines
Frits Schut
V.O. Patents & Trademarks
Marieke Schuurmans
UMC Utrecht
Jacob Seidell
VU
Agaath Sluijter
Medical Delta
Thijs Spigt
Erasmus MC
Marianne van der Steen
Maastricht University
Maarten Steinbuch
Eindhoven University of Technology
Onno van de Stolpe
Galapagos
Werner Verbiest
Janssen Diagnostics
Martine de Vries
LUMC

Edward van Wezel
BioGeneration Ventures

Jan van de Winkel
Genmab

Loek Winter
DC Klinieken

Hanneke Heeres
Health~Holland
Caroline Duterloo
Medical Delta
Paul Korte
Janssen
Sponsors & Partners
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Award sponsor
Award sponsor
© 2017 Innovation for Health